LONDON: AstraZeneca expects profit growth to pick up this year after the COVID-19 vaccine developer beat forecasts for quarterly drug sales, with demand for its cancer and other therapies cushioning the disruption caused by the pandemic. Last year was a crucial one for the Anglo-Swedish company …
